|
EP2081929B1
(en)
|
2006-11-08 |
2013-01-09 |
Neurocrine Biosciences, Inc. |
Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
|
|
SI3061760T1
(en)
|
2008-09-18 |
2018-04-30 |
Auspex Pharmaceuticals, Inc. |
Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
|
|
EP2576552A4
(en)
*
|
2010-06-01 |
2013-11-13 |
Aupex Pharmaceutical Inc |
BENZOQUINOLONE INHIBITORS OF VMAT2
|
|
WO2012000308A1
(zh)
*
|
2010-06-29 |
2012-01-05 |
中国药科大学 |
丁苯那嗪的拆分方法
|
|
US8351329B2
(en)
*
|
2010-09-14 |
2013-01-08 |
Cisco Technology, Inc. |
Universal load-balancing tunnel encapsulation
|
|
CN102285984B
(zh)
*
|
2010-11-25 |
2012-10-10 |
江苏威凯尔医药科技有限公司 |
(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
|
|
WO2012081031A1
(en)
|
2010-12-15 |
2012-06-21 |
Enaltec Labs Pvt. Ltd. |
Process for preparing tetrabenazine
|
|
EP4345100A3
(en)
|
2012-09-18 |
2024-04-10 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
EP2951178A4
(en)
|
2013-01-31 |
2016-07-06 |
Auspex Pharmaceuticals Inc |
VMAT2 INHIBITORS OF BENZOQUINOLONE TYPE
|
|
HK1221645A1
(zh)
*
|
2013-09-27 |
2017-06-09 |
Auspex Pharmaceuticals, Inc. |
Vmat2的苯并喹啉抑制剂
|
|
CN105873589B
(zh)
|
2013-12-03 |
2019-11-01 |
奥斯拜客斯制药有限公司 |
制造苯并喹啉化合物的方法
|
|
CA2936823A1
(en)
*
|
2014-01-27 |
2015-07-30 |
Auspex Pharmaceuticals, Inc. |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
WO2015120110A2
(en)
|
2014-02-07 |
2015-08-13 |
Auspex Pharmaceuticals, Inc. |
Novel pharmaceutical formulations
|
|
JP6718376B2
(ja)
|
2014-02-07 |
2020-07-08 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用
|
|
SI3105218T1
(sl)
|
2014-02-13 |
2019-11-29 |
Incyte Corp |
Ciklopropilamini kot inhibitorji LSD1
|
|
KR20200133003A
(ko)
*
|
2014-05-06 |
2020-11-25 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
과다운동성 운동 장애의 치료를 위한 vmat2 억제제
|
|
MX375718B
(es)
*
|
2015-02-06 |
2025-03-06 |
Neurocrine Biosciences Inc |
[9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
|
|
DK3265085T3
(da)
|
2015-03-06 |
2022-10-03 |
Auspex Pharmaceuticals Inc |
Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser
|
|
US9944647B2
(en)
|
2015-04-03 |
2018-04-17 |
Incyte Corporation |
Heterocyclic compounds as LSD1 inhibitors
|
|
WO2016210180A2
(en)
*
|
2015-06-23 |
2016-12-29 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors for treating neurological diseases or disorders
|
|
SI3334709T1
(sl)
|
2015-08-12 |
2025-03-31 |
Incyte Holdings Corporation |
Soli zaviralca lsd1
|
|
AR106313A1
(es)
|
2015-10-09 |
2018-01-03 |
Teva Pharmaceuticals Int Gmbh |
Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson
|
|
TN2018000121A1
(en)
|
2015-10-30 |
2019-10-04 |
Neurocrine Biosciences Inc |
Valbenazine salts and polymorphs thereof
|
|
LT3394057T
(lt)
|
2015-12-23 |
2022-06-27 |
Neurocrine Biosciences, Inc. |
Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
|
|
WO2017182916A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Lupin Limited |
Novel process for preparation of tetrabenazine and deutetrabenazine
|
|
US10442800B2
(en)
*
|
2016-06-29 |
2019-10-15 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Crystal forms of NBI-98854, preparation method and use thereof
|
|
EP3523300A1
(en)
|
2016-10-06 |
2019-08-14 |
Assia Chemical Industries Ltd. |
Solid state forms of valbenazine
|
|
TW202515564A
(zh)
|
2016-12-02 |
2025-04-16 |
美商紐羅克里生物科學有限公司 |
戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
|
|
WO2018130345A1
(en)
|
2017-01-10 |
2018-07-19 |
Sandoz Ag |
Crystalline valbenazine free base
|
|
WO2018140092A1
(en)
*
|
2017-01-27 |
2018-08-02 |
Obrien Christopher F |
Methods for the administration of certain vmat2 inhibitors
|
|
JP2020508337A
(ja)
|
2017-02-27 |
2020-03-19 |
サンド・アクチエンゲゼルシヤフト |
バルベナジン塩の結晶形態
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
JP7608050B2
(ja)
|
2017-03-15 |
2025-01-06 |
オースペックス ファーマシューティカルズ インコーポレイテッド |
デューテトラベナジンの類似体、その調製及び使用
|
|
GB201705306D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705302D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705305D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
JP7250692B2
(ja)
*
|
2017-04-01 |
2023-04-03 |
アデプティオ ファーマシューティカルズ リミテッド |
運動障害の治療における使用のためのジヒドロテトラベナジン
|
|
GB201705303D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705304D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
JOP20190239A1
(ar)
*
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
US20200276184A1
(en)
|
2017-09-21 |
2020-09-03 |
Neurocrine Biosciences, Inc. |
High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto
|
|
EA202090932A1
(ru)
|
2017-10-10 |
2021-05-20 |
Нейрокрин Байосайенсиз, Инк |
Способы введения некоторых vmat2-ингибиторов
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
JP2021503009A
(ja)
*
|
2017-11-08 |
2021-02-04 |
フォアシー ファーマシューティカルズ シーオー．，リミテッド |
ジヒドロテトラベナジンのエステル
|
|
US11384077B2
(en)
|
2017-11-22 |
2022-07-12 |
Assia Chemical Industries Ltd. |
Solid state form of Valbenazine
|
|
CN110621674B
(zh)
|
2017-12-26 |
2022-03-29 |
苏州科睿思制药有限公司 |
一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
|
|
CN110092785A
(zh)
*
|
2018-01-31 |
2019-08-06 |
广东东阳光药业有限公司 |
一种丁苯那嗪的动态拆分方法
|
|
GB201808464D0
(en)
|
2018-05-23 |
2018-07-11 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compounds for use in treating huntington's disease
|
|
AU2019287524A1
(en)
*
|
2018-06-14 |
2020-12-24 |
Neurocrine Biosciences, Inc. |
VMAT2 inhibitor compounds, compositions, and methods relating thereto
|
|
JP2021528481A
(ja)
|
2018-08-15 |
2021-10-21 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
特定のｖｍａｔ２阻害剤を投与するための方法
|
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|
|
EP3860599B1
(en)
|
2018-10-04 |
2024-05-15 |
Adeptio Pharmaceuticals Limited |
(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
|
|
CA3065236A1
(en)
|
2018-12-27 |
2020-06-27 |
Apotex Inc. |
Novel crystalline form of valbenazine dibesylate
|
|
WO2020213014A1
(en)
|
2019-04-19 |
2020-10-22 |
Mylan Laboratories Limited |
An improved process for the preparation of valbenazine and its salts
|
|
US10689380B1
(en)
|
2019-07-30 |
2020-06-23 |
Farmhispania S.A. |
Crystalline forms of valbenazine ditosylate
|
|
US20220340562A1
(en)
*
|
2019-08-12 |
2022-10-27 |
Shandong Luye Pharmaceutical Co., Ltd. |
Vmat2 inhibitor and preparation method therefor and application thereof
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
EP4028397A1
(en)
|
2019-09-13 |
2022-07-20 |
Neurocrine Biosciences, Inc. |
Processes for the synthesis of valbenazine
|
|
CN110698397A
(zh)
*
|
2019-10-28 |
2020-01-17 |
南京红杉生物科技有限公司 |
丁苯那嗪中间体及其合成方法、应用和合成用中间产物
|
|
CN117062815A
(zh)
|
2021-03-22 |
2023-11-14 |
纽罗克里生物科学有限公司 |
Vmat2抑制剂及使用方法
|
|
US20240239791A1
(en)
|
2021-04-26 |
2024-07-18 |
Neurocrine Biosciences, Inc. |
Processes for the synthesis of valbenazine
|
|
US20240342159A1
(en)
|
2021-06-30 |
2024-10-17 |
Neurocrine Biosciences, Inc. |
Valbenazine for use in the add-on treatment of schizophrenia
|
|
MX2023014977A
(es)
|
2021-06-30 |
2024-02-09 |
Neurocrine Biosciences Inc |
Valbenazina para usarse en el tratamiento de discinesia debido a paralisis cerebral.
|
|
WO2023172849A1
(en)
|
2022-03-07 |
2023-09-14 |
Neurocrine Biosciences, Inc. |
Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
|
|
IL319670A
(en)
|
2022-09-21 |
2025-05-01 |
Neurocrine Biosciences Inc |
VMAT2 inhibitors based on hexahydro-2H-pyridyl-1,2-[A]isoquinoline and methods of use
|
|
WO2025038959A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
TW202521119A
(zh)
|
2023-08-17 |
2025-06-01 |
美商紐羅克里生物科學有限公司 |
用於投與特定vmat2抑制劑之方法
|
|
WO2025096823A1
(en)
|
2023-11-01 |
2025-05-08 |
Neurocrine Biosciences, Inc. |
Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
|
|
WO2025188830A1
(en)
|
2024-03-06 |
2025-09-12 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025199234A1
(en)
|
2024-03-20 |
2025-09-25 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors and methods of use
|